Academic Commons

Articles

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Kaufman, Howard; Taback, Bret; Sherman, William; Kim, Dae; Shingler, William; Moroziewicz, Dorota; DeRaffele, Gail; Mitcham, Josephine; Carroll, Miles; Harrop, Richard; Naylor, Stuart; Kim-Schulze, Seunghee

Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known. 5T4 is a non-secreted membrane glycoprotein expressed on clear cell and papillary RCCs. A modified vaccinia virus Ankara (MVA) encoding 5T4 was tested in combination with high-dose IL-2 to determine the safety, objective response rate and effect on humoral and cell-mediated immunity. 25 patients with metastatic RCC who qualified for IL-2 were eligible and received three immunizations every three weeks followed by IL-2 (600,000 IU/kg) after the second and third vaccinations. Blood was collected for analysis of humoral, effector and regulatory T cell responses. There were no serious vaccine-related adverse events. While no objective responses were observed, three patients (12%) were rendered disease-free after nephrectomy or resection of residual metastatic disease. Twelve patients (48%) had stable disease which was associated with improved median overall survival compared to patients with progressive disease (not reached vs. 28 months, p = 0.0261). All patients developed 5T4-specific antibody responses and 13 patients had an increase in 5T4-specific T cell responses. Although the baseline frequency of Tregs was elevated in all patients, those with stable disease showed a trend toward increased effector CD8+ T cells and a decrease in Tregs. Vaccination with MVA-5T4 did not improve objective response rates of IL-2 therapy but did result in stable disease associated with an increase in the ratio of 5T4-specific effector to regulatory T cells in selected patients. Trial registration number: ISRCTN83977250

Subjects

Files

  • thumnail for b8af1292338f4b4bd9b31c9af48ebf1e.zip b8af1292338f4b4bd9b31c9af48ebf1e.zip binary/octet-stream 683 KB Download File

Also Published In

Title
Journal of Translational Medicine
DOI
https://doi.org/10.1186/1479-5876-7-2

More About This Work

Academic Units
Surgery
Publisher
BioMed Central
Published Here
September 8, 2014